Soft Tissue Sarcoma (STS)SAGESNCT07864870
Sarcoma Care Adherence and Survival in Strasbourg
An observational study of Soft Tissue Sarcoma (STS), run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
This retrospective monocentric study evaluates adherence to international clinical practice guidelines for soft tissue sarcoma management in Strasbourg and its impact on overall survival. It also compares practices and outcomes between two periods (2010-2016 and 2017-2024). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Soft Tissue Sarcoma (STS)
- How many people
- 900 participants
- Where
- 1 siteFrance
- Study dates
- 27 Nov 2025to 27 Mar 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with suspected or confirmed soft tissue sarcoma presented at multidisciplinary tumor boards in Strasbourg between 2017 and 2024
Who may be able to join
- Patient aged 18 years or older at first multidisciplinary tumor board presentation
- Presented for multidisciplinary tumor board evaluation for soft tissue or visceral tumor
- First presentation between 01/01/2017 and 31/12/2024
- Absence of opposition to reuse of medical data for research purposes
Who cannot join
- Presence of opposition to reuse of medical data for research purposes
- Patient younger than 18 years at first presentation
- Bone tumors, gastrointestinal stromal tumors (GIST), or Kaposi sarcoma
- First presentation outside the study period
- Management outside Alsace-Moselle
- Duplicate records
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service d'hématologie-oncologie pédiatrique - CHU de Strasbourg - France
Strasbourg, 67091
Justine Gantzer, MD, 33 3 88 12 88 25, justine.gantzer@chru-strasbourg.fr
Justine Gantzer, MD
About this study
Official title: Sarcoma Adherence to Good Practice and Effect on Survival: A Retrospective Monocentric Study
This retrospective monocentric study evaluates adherence to international clinical practice guidelines for soft tissue sarcoma management in Strasbourg and its impact on overall survival. It also compares practices and outcomes between two periods (2010-2016 and 2017-2024).
- Conditions
- Soft Tissue Sarcoma (STS)
- Keywords
- Sarcoma, Clinical Practice Guidelines, Overall Surviva
- Medical subject headings
- Sarcoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Adherence to Good Clinical Practice and Overall Survival
Evaluation of adherence to international guidelines using DELPHI criteria and assessment of overall survival defined as time from diagnosis to death from any cause
Measured: From diagnosis up to end of follow-up (2017-2024)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start27 Nov 2025
- Primary completion27 Jan 2027 (estimated)
- Study completion27 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Soft Tissue Sarcoma (STS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07864870
- Sponsor's protocol ID
- 9950
- Acronym
- SAGES
- Status last verified
- Oct 2026
- First submitted
- 2 Oct 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No